EP0959925A1 - Nebulizer - Google Patents

Nebulizer

Info

Publication number
EP0959925A1
EP0959925A1 EP96943222A EP96943222A EP0959925A1 EP 0959925 A1 EP0959925 A1 EP 0959925A1 EP 96943222 A EP96943222 A EP 96943222A EP 96943222 A EP96943222 A EP 96943222A EP 0959925 A1 EP0959925 A1 EP 0959925A1
Authority
EP
European Patent Office
Prior art keywords
gas
nebuliser
supply
liquid
nebulizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96943222A
Other languages
German (de)
French (fr)
Inventor
Surinderjit Kumar Jassell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intersurgical Ltd
Original Assignee
Intersurgical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intersurgical Ltd filed Critical Intersurgical Ltd
Publication of EP0959925A1 publication Critical patent/EP0959925A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles

Definitions

  • Nebulizers are becoming widely used in hospitals and other medical situations. Such as
  • nebulizers have particular application in the delivery of drugs for the treatment of lung diseases.
  • ⁇ e drug may be given as an inhaled drug aerosol, and this has many advantages over drugs which are taken systemically. It has become apparent that the size of the droplets plays an important role in how the drug is received by
  • the present invention provides a nebulizer comprising a pressure gas inlet, means for passing liquid medication to nebulising means associated with said pressure gas inlet
  • the nebulizer may include a reservoir for said liquid medication, and the control means may include means to vary the size of the supply means so as to vary the amount of further gas passing through said further gas supply means.
  • the control means may be in the form of a variable aperture, which may be provided by an aperture with a plate with a cooperating aperture therein, the plate being moveable.
  • the control means may also include a one way valve.
  • An advantage of the arrangement of the invention is that the quantity and relative constitution of the nebulized mixture may be changed by varying the control means to control the supply of further gas.
  • Figure 3 is a view similar to Figure 2 of the nebulizer with the air controller in a second position
  • Figure 4 is a view corresponding to Figures 2 and 3 of the nebulizer, with the air controller missing, showing the inlet air valve,
  • Figure 5 is a pan view showing one line of ratchet teeth mounted on the nebul ⁇ zer( with air controller missing), and,
  • Figure 6 is rear view of the air controller showing the teeth to engage the ratchet shown in Figure 5.
  • FIG. 1 there is shown an axial section through a nebulizer (10).
  • the section shown in Figure 1 comp ⁇ ses, on the left hand side of the Figure 1 , a first ve ⁇ ical section, and on the ⁇ ght hand side of the Figure a second ve ⁇ icaJ section at ⁇ ght angles to the first
  • the nebulizer is manufactured of ⁇ gid moulded plastics mate ⁇ al.
  • the nebulizer compnses a base section (1 1) which includes an inlet tube ( 12) for connection to a flexible plastic tube supplying pressurized gas, such as oxygen or air.
  • the inlet tube (12) is sunounded by a threaded collar (13).
  • Forming pan of the base section ( 1 1) but separately moulded is a second moulding ( 16) which includes; (a) a cylindncal stem portion (17) which closely sunounds the
  • a jet mounting portion which includes a jet (20A) which overlies a jet (20B) in the upper end of the inlet (12); and (c) a collar portion (21 ) which comprises a frusto conical plate (22) surrounding the jet mounting po ⁇ ion (19) and
  • the inner generally cylindrical surface (21A) of the collar portion (21) immediately sunounding the jet comprises a frusto-conical surface of the apex of which is below the collar and is at an angle of about 8° to the axis.
  • the jet (20A) and jet (20B) combine to provide a gas/liquid mixing jet (20).
  • the collar (32) communicates via pathways (33, 34) with an ambient air inlet (36) mounted on the side of the outer housing (27).
  • the ambient air inlet (36) is closed by a one way valve (37) in the form of a flexible diaphragm (38) of plastic, neoprene, or rubber mounted centrally at (39) and which engages with a rim (41) sunounding the ambient air inlet (36).
  • the ambient air inlet (36) includes a circular opening (42) defined by the rim (41) and an adjustable air controller (43) is provided
  • the adjustable air controller (43) comprises a plate like member (44) mounted to slide vertically with respect to the housing (27) and includes an aperture (46) which, as the plate (44) slides, may selectively align with the circular opening (42).
  • Figure 2 shows the general arrangement of the plate (44), in a first position in which the air inlet (36) is closed and
  • Figure 3 shows the plate (44) in a second position in which the air inlet (36) is open.
  • Figures 4 shows the nebulizer with the plate (44) removed thereby showing more clearly the circular opening (42).
  • each side of the opening (42) there is moulded into the outer housing (27) a pair of vertically extending edges (47, 48) which each include a respective ratchet track (51 , 52) which are illustrated in more detail in Figure 5.
  • the plate (44) Spaced from and aligned into the conesponding vertically extending edges (47, 48), the plate (44) has ve ⁇ ically extending faces (53, 54) illustrated in Figure 6.
  • Each face (53.54) includes a respective upper and lower tooth (56, 57) for engaging with the respective adjacent ratchet track (51 , 52).
  • inlet tube (12) is connected by means of a flexible plastic pipe to a suitable pressurised supply of air or oxygen and the outlet (28) is connected, usually by tubes, to a patient.
  • the plate (44) is slid up or down so that the aperture (46) coincides with the circular opening (42) to a desired extent and is held in the desired position by engagement of the teeth (56,57) with their respective ratchet tracks (51 ,52).
  • the liquid medication passes from top reservoir (14) up the capillary path (18) and as the pressurised air or oxygen passes through the jet (20B), mixes with the liquid passing
  • air is drawn into the ambient air inlet (36) via the one way valve (37), through the pathways (33,34) to join and mix with the nebulized stream assisting in the breaking up of the gas liquid stream into finer droplets and in increasing the aerosol output being delivered through the outlet (28).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nozzles (AREA)

Abstract

A nebuliser comprising a pressure gas inlet (12), means (18) for passing liquid medication to nebulising means (20) associated with said pressure gas inlet to mix gas from the pressure gas inlet with said liquid medication to produce a nebulised mixture of liquid and gas, means (36) to supply further gas, to mix with said nebulised mixture, said further gas supply means including a control means (43) to control said supply of said further gas.

Description

NEBULIZER
The present invention relates to nebulizers. Nebulizers are used to produce a liquid m fine droplet form in a gas flow, typically a liquid in the form of medication which is to be entrained in an air or oxygen gas flow and which is then breathed by a patient whereby the medication is supplied to the patient through the lungs.
Nebulizers are becoming widely used in hospitals and other medical situations. Such
nebulizers have particular application in the delivery of drugs for the treatment of lung diseases. Thus ±e drug may be given as an inhaled drug aerosol, and this has many advantages over drugs which are taken systemically. It has become apparent that the size of the droplets plays an important role in how the drug is received by
the lungs.
European Patent specification EP-A-573457 demonstrates a typical nebulizer and there is included in that specification details of the effect of droplet size on the delivery of the medicauon.
The present invention provides a nebulizer comprising a pressure gas inlet, means for passing liquid medication to nebulising means associated with said pressure gas inlet
to mix gas from the pressure gas inlet with said liquid medication to produce a nebulized mixture of liquid and gas, means to supply further gas, which may be ambient air, to mix with said nebulized mixture, said further gas supply means including a control means to control said supply of said further gas.
The nebulizer may include a reservoir for said liquid medication, and the control means may include means to vary the size of the supply means so as to vary the amount of further gas passing through said further gas supply means. The control means may be in the form of a variable aperture, which may be provided by an aperture with a plate with a cooperating aperture therein, the plate being moveable. The control means may also include a one way valve.
An advantage of the arrangement of the invention is that the quantity and relative constitution of the nebulized mixture may be changed by varying the control means to control the supply of further gas. By providing the control means at the input to the nebuliser, there is less risk of these control means being contaminated with medication.
A nebulizer incoφorating a preferred embodiment of the invention will now. be
described by way of example only with reference to the accompanying drawings in which:-
Figure 1 is a axial section through a nebulizer according to the invention, Figure 2 is a perspective view of the nebulizer of Figure 1 from the right
hand side with an air controller in a first position, similar to the position shown in
Figure 1 ,
Figure 3 is a view similar to Figure 2 of the nebulizer with the air controller in a second position,
Figure 4 is a view corresponding to Figures 2 and 3 of the nebulizer, with the air controller missing, showing the inlet air valve,
Figure 5 is a pan view showing one line of ratchet teeth mounted on the nebulιzer( with air controller missing), and,
Figure 6 is rear view of the air controller showing the teeth to engage the ratchet shown in Figure 5.
Referring to Figure 1 , there is shown an axial section through a nebulizer (10). The section shown in Figure 1 , compπses, on the left hand side of the Figure 1 , a first veπical section, and on the πght hand side of the Figure a second veπicaJ section at πght angles to the first The nebulizer is manufactured of πgid moulded plastics mateπal. The nebulizer compnses a base section (1 1) which includes an inlet tube ( 12) for connection to a flexible plastic tube supplying pressurized gas, such as oxygen or air. The inlet tube (12) is sunounded by a threaded collar (13).
Surrounding the pan of the inlet tube (12) which extends into the base section (11)
is a reservoir (14) for liquid medication.
Forming pan of the base section ( 1 1) but separately moulded is a second moulding ( 16) which includes; (a) a cylindncal stem portion (17) which closely sunounds the
inlet tube (12) where it protrudes into the reservoir (14) and provides therebetween a capillary path (18) from the base of the reservoir (14) to the top of the inlet tube (12). (b) a jet mounting portion ( 19) which includes a jet (20A) which overlies a jet (20B) in the upper end of the inlet (12); and (c) a collar portion (21 ) which comprises a frusto conical plate (22) surrounding the jet mounting poπion (19) and
mounted thereon by legs (25). The inner generally cylindrical surface (21A) of the collar portion (21) immediately sunounding the jet comprises a frusto-conical surface of the apex of which is below the collar and is at an angle of about 8° to the axis. The jet (20A) and jet (20B) combine to provide a gas/liquid mixing jet (20).
An upper section (26) screw threadedly engages with the upper edge of the base section (1 1) and comprises an outer housing (27) at the upper end of which is provided an outlet (28) for air and nebulized medication, and within the housing (27) is mounted a cylindrical stub (29) which forms a target (31) disposed immediately opposite the jet (20) , the cylindrical stub (29) being sunounded by a downwardly extending collar (32) which engages axially with the collar portion (21).
The collar (32) communicates via pathways (33, 34) with an ambient air inlet (36) mounted on the side of the outer housing (27). The ambient air inlet (36) is closed by a one way valve (37) in the form of a flexible diaphragm (38) of plastic, neoprene, or rubber mounted centrally at (39) and which engages with a rim (41) sunounding the ambient air inlet (36). The ambient air inlet (36) includes a circular opening (42) defined by the rim (41) and an adjustable air controller (43) is provided
to selectively obscure the circular opening (42) as will be described hereafter.
The adjustable air controller (43) comprises a plate like member (44) mounted to slide vertically with respect to the housing (27) and includes an aperture (46) which, as the plate (44) slides, may selectively align with the circular opening (42). Figure 2 shows the general arrangement of the plate (44), in a first position in which the air inlet (36) is closed and Figure 3 shows the plate (44) in a second position in which the air inlet (36) is open. Figures 4 shows the nebulizer with the plate (44) removed thereby showing more clearly the circular opening (42).
On each side of the opening (42) there is moulded into the outer housing (27) a pair of vertically extending edges (47, 48) which each include a respective ratchet track (51 , 52) which are illustrated in more detail in Figure 5. Spaced from and aligned into the conesponding vertically extending edges (47, 48), the plate (44) has veπically extending faces (53, 54) illustrated in Figure 6. Each face (53.54) includes a respective upper and lower tooth (56, 57) for engaging with the respective adjacent ratchet track (51 , 52).
In operation the base section ( 1) and upper section (26) are separated and suitable
medication is poured into the reservoir (14) of the base section (1 1). The base section (1 1) and upper section (26) are then reengaged in a manner shown in Figure
1, inlet tube (12) is connected by means of a flexible plastic pipe to a suitable pressurised supply of air or oxygen and the outlet (28) is connected, usually by tubes, to a patient. The plate (44) is slid up or down so that the aperture (46) coincides with the circular opening (42) to a desired extent and is held in the desired position by engagement of the teeth (56,57) with their respective ratchet tracks (51 ,52). The liquid medication passes from top reservoir (14) up the capillary path (18) and as the pressurised air or oxygen passes through the jet (20B), mixes with the liquid passing
up the capillary path (18) and together pass through the jet (20A), the nebulised gas/liquid jet then striking the target (31) to break up the liquid panicles. The aerosol formed then passes down between the jet mounting portion (19) and the inner surface of the frusto conical plate (22). The frusto conical plate (22) and the inner cylindrical surface (21 A) of the collar (21 ) collect the remaining larger droplets in the nebulized stream (which take a different, less tortuous trajectory and thus strike these surfaces) and the nebulized stream then passes up through the outlet (28). The collected liquid drips off the lowermost edge of the collar (21) back into the reservoir (14). In addition to the nebulized stream, air is drawn into the ambient air inlet (36) via the one way valve (37), through the pathways (33,34) to join and mix with the nebulized stream assisting in the breaking up of the gas liquid stream into finer droplets and in increasing the aerosol output being delivered through the outlet (28).
It will be understood, therefore, that by varying the amount of air drawn into the ambient air inlet (36) by sliding the adjustable air controller (43) plate (44) up and
down, one can vary the proportion of medication to air.
By arranging the adjustable air controller (43) at the air inlet, one avoids a number
of problems. For example as most of the nebulized stream passes out of the outlet of the nebulizer, very little if any of the nebulized liquid will be deposited on the adjustable air controller, which would otherwise be a problem.

Claims

1. A nebuliser comprising a pressure gas inlet (12), means (18) for passing liquid medication to nebulising means (20) associated with said pressure gas inlet to mix gas from the pressure gas inlet with said liquid medication to produce a nebulised mixture of liquid and gas, means (36) to supply further gas, to mix with said nebulised mixture, said further gas supply means including a control means (43) to control said supply of said further gas.
2. A nebuliser as claimed in claim 1 in which the control means includes means to vary the size of the supply means so as to vary the amount of further gas passing through said further gas supply means.
3. A nebuliser as claimed in claimed 1 or 2 in which the control means is in the form of a variable aperture, provided by an aperture with a plate with a cooperating aperture therein, the plate being moveable.
4. A nebuliser as claimed in claim 1 in any of claims 1 to 3 in which the control means includes a one way valve.
5. A nebuliser as claimed in any of claims 1 to 4 including a reservoir for said liquid medication.
6. A nebuliser as claimed in claim 1 substantially as hereinbefore described with reference to the drawings.
EP96943222A 1995-12-20 1996-12-20 Nebulizer Withdrawn EP0959925A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9526100A GB9526100D0 (en) 1995-12-20 1995-12-20 Nebulizer
GB9526100 1995-12-20
PCT/GB1996/003201 WO1997022376A1 (en) 1995-12-20 1996-12-20 Nebulizer

Publications (1)

Publication Number Publication Date
EP0959925A1 true EP0959925A1 (en) 1999-12-01

Family

ID=10785782

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96943222A Withdrawn EP0959925A1 (en) 1995-12-20 1996-12-20 Nebulizer

Country Status (4)

Country Link
EP (1) EP0959925A1 (en)
AU (1) AU1201797A (en)
GB (1) GB9526100D0 (en)
WO (1) WO1997022376A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
PT2308888T (en) 2001-11-14 2017-05-03 Janssen Biotech Inc Anti-il-6 antibodies, compositions, methods and uses
AU2003280130B2 (en) 2002-06-28 2009-06-11 Centocor, Inc. Mammalian CH1 deleted mimetibodies, compositions, methods and uses
UA89481C2 (en) 2003-09-30 2010-02-10 Центокор, Инк. Human epo mimetic hinge core mimetibodies, compositions, methods and uses
KR20070004078A (en) 2004-03-31 2007-01-05 센토코 인코포레이티드 Human glp-1 mimetibodies, compositions, methods and uses
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
JO3058B1 (en) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc Anti-IL-6 Antibodies,Compositions,Methods and uses
WO2007005955A2 (en) 2005-06-30 2007-01-11 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
EA035459B1 (en) 2005-12-29 2020-06-19 Сентокор, Инк. ANTI-IL-23p19 ANTIBODY
JP2010500360A (en) 2006-08-10 2010-01-07 アルボア コーポレーション Local therapy of lower respiratory inflammatory diseases with inflammatory cytokine inhibitors
UY30820A1 (en) 2006-12-21 2008-07-03 Centocor Inc USE OF LONG-TERM ACTION GLP-1 RECEPTOR AGONISTS TO IMPROVE INSULIN SENSITIVITY AND LIPID PROFILES
CA2733642A1 (en) 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
KR101781907B1 (en) 2008-10-31 2017-09-26 얀센 바이오테크 인코포레이티드 Fibronectin type iii domain based scaffold compositions, methods and uses
EP2396011B1 (en) 2009-02-12 2016-04-13 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
MX341687B (en) 2010-02-10 2016-08-30 Immunogen Inc Cd20 antibodies and uses thereof.
EP4269563A3 (en) 2010-06-19 2024-01-10 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
TWI718086B (en) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
JP6482525B2 (en) 2013-03-15 2019-03-13 メモリアル スローン ケタリング キャンサー センター High affinity anti-GD2 antibody
IL296062A (en) 2015-03-17 2022-10-01 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
CN109715670A (en) 2016-07-15 2019-05-03 波赛达治疗公司 To the Chimeric antigen receptor (CAR) and its application method of MUC1 specificity
WO2018014038A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
CA3051484A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
CN110234351A (en) 2017-01-30 2019-09-13 詹森生物科技公司 For treating the anti-TNF antibodies, composition and method of activity psoriatic arthritis
JP2020506947A (en) 2017-02-07 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド Anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis
AU2018393110B2 (en) 2017-12-20 2023-04-27 Poseida Therapeutics, Inc. VCAR compositions and methods for use
EP3790587A4 (en) 2018-05-11 2022-01-26 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies
CA3126654A1 (en) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
MX2021008871A (en) 2019-01-23 2021-08-19 Janssen Biotech Inc Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis.
EP3938391A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
JP2022525179A (en) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド Production method for producing anti-TNF antibody composition
US20220153829A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Methods for Producing Anti-TNF Antibody Compositions
BR112021023295A2 (en) 2019-05-23 2022-02-08 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf-alpha
WO2020245676A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
KR20220030952A (en) 2019-06-03 2022-03-11 얀센 바이오테크 인코포레이티드 Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
CA3174777A1 (en) 2020-04-14 2021-10-21 Eric M. Ostertag Compositions and methods for use in the treatment of cancer
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
AU2021315818A1 (en) 2020-07-31 2023-03-23 Pinetree Therapeutics, Inc. Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections
WO2023279115A1 (en) 2021-07-02 2023-01-05 Henry Ford Health System Compositions comprising endosidin 2 for reducing sars-cov-2 infection
CN117957251A (en) 2021-07-09 2024-04-30 詹森生物科技公司 Method for preparing anti-TNF antibody compositions
US20230040065A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194258A1 (en) * 1984-09-18 1986-09-17 Vortran Corporation All purpose nebulizer
EP0261649B2 (en) * 1986-09-22 1995-04-26 Omron Tateisi Electronics Co. Nebulizer
DE3636669C2 (en) * 1986-10-28 2001-08-16 Siemens Ag Arrangement for delivering aerosol to a patient's airways and / or lungs
US5301662A (en) * 1991-09-25 1994-04-12 Cimco, Inc. Nebulizer with high oxygen content and high total flow rate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9722376A1 *

Also Published As

Publication number Publication date
WO1997022376A1 (en) 1997-06-26
AU1201797A (en) 1997-07-14
GB9526100D0 (en) 1996-02-21

Similar Documents

Publication Publication Date Title
WO1997022376A1 (en) Nebulizer
US7726306B2 (en) Intra-oral nebulizer with rainfall chamber
EP0880373B1 (en) Nebulizer apparatus
AU712312B2 (en) Breathing circuit apparatus for a nebulizer
US9907918B2 (en) Nebulizer apparatus and method
US7712466B2 (en) Intra-oral nebulizer
EP0653946B1 (en) Low flow rate nebulizer
CA1130160A (en) Nebulizer with variable flow rate control
US7493898B2 (en) Inhalation apparatus
DE19726110A1 (en) Ultrasound misting unit for breathing systems
US8439030B2 (en) Nebulizer device
AU2004202959B2 (en) Nebulizer Apparatus and Method
AU771684B2 (en) Nebulizer apparatus and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980626

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

17Q First examination report despatched

Effective date: 20021127

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030408